{"id":423864,"date":"2024-01-02T02:39:56","date_gmt":"2024-01-02T07:39:56","guid":{"rendered":"https:\/\/platohealth.ai\/alfasigma-spa-signs-e170m-deal-with-galapagos-nv\/"},"modified":"2024-01-02T03:08:46","modified_gmt":"2024-01-02T08:08:46","slug":"alfasigma-spa-signs-e170m-deal-with-galapagos-nv","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/alfasigma-spa-signs-e170m-deal-with-galapagos-nv\/","title":{"rendered":"Alfasigma SpA signs \u20ac170m deal with Galapagos NV","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n
\n

Following its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the \u20ac170m deal.\n<\/p>\n<\/p><\/div>\n

\n

With the transaction<\/a> that is expected to close in Q1\/2024, Alfasigma will strengthen its pipeline, add a new Phase III programme to expand filgotinib\u2019s label to a third indication. Aditionally, Alfasigma expects to significantly expand its presence in the Northern European markets and will strengthen its presence in Southern Europe through the acquisition.\n<\/p>\n

Under the terms of the agreement, Alfasigma will acquire the entire filgotinib business, including the European and UK marketing authorizations, the commercial, medical affairs and development activities for filgotinib and 400 Galapagos positions in 14 European countries. Galapagos<\/a> will receive a \u20ac50m upfront payment, potential milestone payments totalling \u20ac120m and mid-single to mid-double-digit sales-based payments on European sales. Galapagos will contribute up to \u20ac40m to Alfasigma by June 2025 for filgotinib-related development activities.\n<\/p>\n

Subject to and as part of the closing, Michele Manto, Galapagos\u2019 former Chief Commercial Officer, will join Alfasigma as Chief Commercial Officer Western Europe. <\/p>\n<\/p><\/div>\n